The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Comparing the efficacy and curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL
Gloria Iacoboni, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, comments on the key points of a debate around the curative potential of CAR-T therapy and bispecific antibodies in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). According to Dr Iacoboni, CAR-T therapy remains the preferred option currently as there is more long-term follow-up data from trials and from the real-world demonstrating the efficacy and curative potential of this treatment modality.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
NOVARTIS, KITE/GILEAD, BMS/CELGENE, ASTRAZENECA, ROCHE, ABBVIE, JANSSEN, MILTENYI: Honoraria; NOVARTIS, KITE/GILEAD, BMS/CELGENE: Consultancy.
